394 related articles for article (PubMed ID: 28220021)
1. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
2. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
Martín-Richard M; Massutí B; Pineda E; Alonso V; Marmol M; Castellano D; Fonseca E; Galán A; Llanos M; Sala MA; Pericay C; Rivera F; Sastre J; Segura A; Quindós M; Maisonobe P;
BMC Cancer; 2013 Sep; 13():427. PubMed ID: 24053191
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Pavel M; Ćwikła JB; Lombard-Bohas C; Borbath I; Shah T; Pape UF; Capdevila J; Panzuto F; Truong Thanh XM; Houchard A; Ruszniewski P
Eur J Cancer; 2021 Nov; 157():403-414. PubMed ID: 34597974
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
[TBL] [Abstract][Full Text] [Related]
10. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
11. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
12. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract][Full Text] [Related]
13. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
15. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
16. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
[TBL] [Abstract][Full Text] [Related]
18. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
[TBL] [Abstract][Full Text] [Related]
20. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.
Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B
Digestion; 1999; 60(5):469-76. PubMed ID: 10473972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
